SK138199A3 - Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus - Google Patents

Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus Download PDF

Info

Publication number: SK138199A3
Authority: SK; Slovakia
Prior art keywords: hpv; concentration; seq; protein; human papillomavirus
Prior art date: 1997-04-08

Application number

SK1381-99A

Other languages

English (en)

Slovak (sk)

Inventor

Gautum Sanyal

David B Volkin

Li Shi

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-08

Filing date

1998-04-07

Publication date

2000-06-12

1997-05-07 Priority claimed from GBGB9709351.2A external-priority patent/GB9709351D0/en

1998-04-07 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2000-06-12 Publication of SK138199A3 publication Critical patent/SK138199A3/sk

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Plant Substances (AREA)

SK1381-99A 1997-04-08 1998-04-07 Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus SK138199A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4280897P	1997-04-08	1997-04-08
GBGB9709351.2A GB9709351D0 (en)	1997-05-07	1997-05-07	Stabilized human papillomavirus formulations
PCT/US1998/006825 WO1998044944A2 (en)	1997-04-08	1998-04-07	Stabilized human papillomavirus formulations

Publications (1)

Publication Number	Publication Date
SK138199A3 true SK138199A3 (en)	2000-06-12

Family

ID=26311501

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1381-99A SK138199A3 (en)	1997-04-08	1998-04-07	Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus

Country Status (18)

Country	Link
EP (1)	EP0973546B1 (de)
JP (1)	JP4598201B2 (de)
KR (1)	KR20010006169A (de)
CN (1)	CN1259051A (de)
AT (1)	ATE261734T1 (de)
AU (1)	AU739829B2 (de)
CA (1)	CA2286294A1 (de)
DE (1)	DE69822452T2 (de)
DK (1)	DK0973546T3 (de)
EE (1)	EE9900612A (de)
ES (1)	ES2216280T3 (de)
IL (1)	IL132201A0 (de)
NO (1)	NO994879L (de)
NZ (1)	NZ500028A (de)
PL (1)	PL336715A1 (de)
PT (1)	PT973546E (de)
SK (1)	SK138199A3 (de)
WO (1)	WO1998044944A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPP765398A0 (en)	1998-12-11	1999-01-14	University Of Queensland, The	Treatment of papillomavirus infections
ATE413188T1 (de) *	1999-02-05	2008-11-15	Merck & Co Inc	Menschliche papillomavirus impfstoff- formulierungen
US6245568B1 (en)	1999-03-26	2001-06-12	Merck & Co., Inc.	Human papilloma virus vaccine with disassembled and reassembled virus-like particles
DE10137102A1 (de)	2001-07-30	2003-02-27	Deutsches Krebsforsch	Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
TW200806315A (en) *	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
KR101515489B1 (ko)	2006-09-29	2015-04-30	다케다 백신즈 인코포레이티드	노로바이러스 백신 제제
CA2698397C (en)	2007-09-18	2018-03-27	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
WO2009092113A2 (en) *	2008-01-19	2009-07-23	Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods and compositions for the delivery of vaccines to disrupted epithelium
RS54687B1 (en) *	2010-12-14	2016-08-31	Glaxosmithkline Biologicals S.A.	COMPOSITION OF MYCOBACTERIAL ANTIGENS
CN102085354A (zh) *	2010-12-30	2011-06-08	重庆大学	一种治疗人乳头瘤病毒16型引发的肿瘤的多肽药物
ES2926487T3 (es)	2011-07-11	2022-10-26	Takeda Vaccines Inc	Formulaciones parenterales de vacunas de norovirus
CN105177025B (zh) *	2013-12-03	2022-11-01	北京康乐卫士生物技术股份有限公司	18型重组人乳头瘤病毒病毒样颗粒及其制备方法
EA201790365A1 (ru) *	2014-09-11	2017-07-31	Кадила Хелзкэр Лимитед	Антигены вируса папилломы человека с хорошими иммунологическими свойствами и содержащая их вакцина
CN106399329B (zh) *	2015-08-12	2021-06-11	北京康乐卫士生物技术股份有限公司	33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106701797B (zh) *	2015-08-12	2021-06-15	北京康乐卫士生物技术股份有限公司	31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN108201623A (zh) *	2016-12-19	2018-06-26	无锡鑫连鑫生物医药科技有限公司	人乳头瘤病毒重组四价疫苗、其制备方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2949031A1 (de) *	1978-12-15	1980-07-17	Sandoz Ag	Vakzine
WO1995015768A1 (de) *	1993-12-09	1995-06-15	Heinrich Exner	Adjuvans für antigene, verfahren zur herstellung und verwendung
AUPM566794A0 (en) *	1994-05-17	1994-06-09	University Of Queensland, The	Process and product
AR004464A1 (es) *	1994-11-14	1998-12-16	Merck Sharp & Dohme	Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) *	1995-03-22	2005-11-20	Merck & Co Inc	Dna encoding human papillomavirus type 18
IL117591A0 (en) *	1995-03-30	1996-07-23	Merck & Co Inc	Synthetic DNA encoding human papillomavirus type 11 L1 protein

1998
- 1998-04-07 NZ NZ500028A patent/NZ500028A/en unknown
- 1998-04-07 KR KR1019997009248A patent/KR20010006169A/ko not_active Application Discontinuation
- 1998-04-07 CN CN98805728A patent/CN1259051A/zh active Pending
- 1998-04-07 IL IL13220198A patent/IL132201A0/xx unknown
- 1998-04-07 WO PCT/US1998/006825 patent/WO1998044944A2/en active IP Right Grant
- 1998-04-07 PT PT98915319T patent/PT973546E/pt unknown
- 1998-04-07 ES ES98915319T patent/ES2216280T3/es not_active Expired - Lifetime
- 1998-04-07 DE DE69822452T patent/DE69822452T2/de not_active Expired - Lifetime
- 1998-04-07 DK DK98915319T patent/DK0973546T3/da active
- 1998-04-07 SK SK1381-99A patent/SK138199A3/sk unknown
- 1998-04-07 EE EEP199900612A patent/EE9900612A/xx unknown
- 1998-04-07 PL PL98336715A patent/PL336715A1/xx unknown
- 1998-04-07 AT AT98915319T patent/ATE261734T1/de not_active IP Right Cessation
- 1998-04-07 CA CA002286294A patent/CA2286294A1/en not_active Abandoned
- 1998-04-07 JP JP54301498A patent/JP4598201B2/ja not_active Expired - Fee Related
- 1998-04-07 EP EP98915319A patent/EP0973546B1/de not_active Expired - Lifetime
- 1998-04-07 AU AU69533/98A patent/AU739829B2/en not_active Ceased
1999
- 1999-10-07 NO NO994879A patent/NO994879L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2286294A1 (en)	1998-10-15
AU739829B2 (en)	2001-10-18
IL132201A0 (en)	2001-03-19
PL336715A1 (en)	2000-07-03
DE69822452T2 (de)	2006-04-20
CN1259051A (zh)	2000-07-05
ATE261734T1 (de)	2004-04-15
NO994879L (no)	1999-12-07
DE69822452D1 (de)	2004-04-22
EP0973546A2 (de)	2000-01-26
DK0973546T3 (da)	2004-06-28
ES2216280T3 (es)	2004-10-16
NZ500028A (en)	2001-08-31
KR20010006169A (ko)	2001-01-26
JP2001519814A (ja)	2001-10-23
EE9900612A (et)	2000-08-15
WO1998044944A2 (en)	1998-10-15
JP4598201B2 (ja)	2010-12-15
PT973546E (pt)	2004-06-30
AU6953398A (en)	1998-10-30
NO994879D0 (no)	1999-10-07
EP0973546B1 (de)	2004-03-17
WO1998044944A3 (en)	1998-12-30

Publication	Publication Date	Title
US6159729A (en)	2000-12-12	Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1 protein
CA2189882C (en)	2005-09-20	Papillomavirus vaccines
SK138199A3 (en)	2000-06-12	Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus
KR101203403B1 (ko)	2012-11-21	효모에서 ｈｐｖ 52 ｌ1의 최적화된 발현
US5821087A (en)	1998-10-13	Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
EP0817851B1 (de)	2004-02-18	Für menschliches papillomavirus stamm 18 kodierende dns
HUT77559A (hu)	1998-06-29	Tisztított papillomavírus-proteinek
US5888516A (en)	1999-03-30	Recombinant papillomavirus vaccines
US6358744B1 (en)	2002-03-19	Stabilized human papillomavirus formulations
CZ356799A3 (cs)	2000-04-12	Prostředek obsahující antigen lidského papilomaviru
CA2216827C (en)	2007-06-26	Synthetic hpv6/11 hybrid l1 dna encoding human papillomavirus type 11 l1 protein